Introduction {#Sec1}
============

Vascular calcification is common in hemodialysis (HD) patients and increases the risk of cardiovascular (CV) disease \[[@CR1]\]. Recently, interest has grown in the relationships between serum magnesium (Mg) levels and vascular calcification or mortality in HD patients \[[@CR2]\]. Extracellular magnesium accounts for only 1% of the total body content \[[@CR3], [@CR4]\]. Serum contains a much smaller amount (0.3% of total body stores), of which one-third is bound to protein, and nonprotein bound magnesium is the fraction that is ultrafilterable in HD and consists of complexed and free magnesium (5.5% and 61% of total serum levels, respectively) \[[@CR4]\]. Normal Mg concentration is 1.7--2.4 mg/dl, and magnesium homeostasis is determined by the balance between absorption and excretion (intestinal and renal) \[[@CR3], [@CR4]\]. In experimental studies, magnesium inhibited vascular calcification and osteogenic differentiation in vitro \[[@CR5]\], prevented calciprotein particle maturation, which can induce calcification in vitro \[[@CR6]\], and bound to phosphate in the intestines, which reduced vascular calcification in rats \[[@CR7]\]. In clinical studies, the follow-up periods used in previous large studies have been short \[[@CR8], [@CR9]\]; notably, few interventional studies have been performed \[[@CR2], [@CR10]\]. Clinical studies have produced inconsistent results regarding the association between Mg levels and mortality, partly because hypomagnesemia is linked to an increased frequency of co-morbidities. It is unclear whether hypomagnesemia causes increased mortality as an independent risk factor or as an "innocent bystander" \[[@CR11]\].

This study was undertaken to investigate the associations between hypomagnesemia and all-cause as well as CV mortality in maintenance hemodialysis (MHD) patients.

Materials and methods {#Sec2}
=====================

This prospective observational study included 353 unselected patients that received MHD during September 2014 at Ichiyokai Hospitals. Patients who met any of the following criteria were excluded: age \< 20 years old, had been on dialysis for \< 3 months, had a history of advanced cancer, had experienced an infection in the past month, or had undergone organ transplantation. All patients underwent 4-h HD sessions, with high-flux membranes and standard bicarbonate dialysis fluid (140 mEq/l sodium, 2.0 mEq/l potassium, 3.0 mEq/l calcium, 1.0 mEq/l magnesium, and 100 mg/dl glucose) using central dialysis fluid delivery system, 3 times per week. Patients' baseline characteristics, including information regarding age, gender, primary kidney disease, dialysis vintage, presence of diabetes mellitus, and current use of warfarin, were obtained from the institutional database. Blood pressure values, Kt/Vurea, Mg, serum albumin, high-sensitivity C-reactive protein (hsCRP), potassium, phosphate, uric acid, intact parathyroid hormone (iPTH), intact fibroblast growth factor 23 (FGF23), albumin-adjusted serum calcium levels, normalized protein nitrogen appearance (nPNA), and geriatric nutritional risk index (GNRI) were measured at baseline, just before or after (for Kt/Vurea alone) the first dialysis session of the first week in September 2014. Furthermore, 24-h urinary volume was evaluated 1 day before baseline blood sampling. Urine volume ≥ 100 ml/day was used as a surrogate marker for residual renal function; no residual renal function was defined as urine volume \< 100 ml/day in this study. The average ultrafiltration/body weight before treatment in the first hemodialysis session of the week in September 2014 (ml/kg/h) was also evaluated. The coronary artery calcium score (CACS) was assessed using the Agatston score \[[@CR12]\], which was obtained from thoracoabdominal multi-detector computed tomography with an Aquilion 64 TSX-101A (Toshiba Medical Systems, Tokyo, Japan). The all-cause and CV mortalities during the follow-up period (from September 2014 to September 2017) were confirmed based on documentation. The CV mortality rate was calculated based on deaths due to CV disease (coronary artery disease, aortic aneurysms, cerebral infarction, cerebral hemorrhage, and/or peripheral artery disease). Patients were followed until death or the end of the study (for 1095 days); their Mg and serum hsCRP levels were determined by BML, Inc. (Tokyo, Japan). A colorimetric method for quantitative Mg determination (Clonemate MG reagent; Sekisui Medical, Tokyo, Japan) was used, which has a normal range of 1.7 to 2.4 mg/dl in the general population and a coefficient of variation of approximately 0.83--1.71%. Serum FGF23 levels were determined by SRL, Inc. (Tokyo, Japan), which used a sandwich enzyme-linked immunosorbent assay kit (Kainos Laboratories, Tokyo, Japan). Our hospital's laboratory performed the remaining clinical biochemical analyses.

Statistical analysis {#Sec3}
--------------------

All statistical analyses were performed with JMP 13 (SAS Institute Japan, Tokyo, Japan). Data for categorical variables are shown as numbers of patients (percentages); data for continuous variables are shown as mean ± standard deviation (SD) or median values and interquartile range (IQR), as appropriate. The significance of inter-group differences was analyzed with the Kruskal--Wallis test, or *χ*^2^ test, as appropriate. Kaplan--Meier 3-year cumulative survival for all-cause deaths and CV deaths was compared between patients with Mg level below the median value and patients with Mg level above the median value in all subjects and subgroups according to serum albumin quartiles. Hazard ratios (HRs) for all-cause and CV death, with associated 95% confidence intervals (CIs), were calculated with the use of a stratified Cox proportional-hazards model. Univariate and multivariate Cox proportional-hazards models were used to determine the factors associated with 3-year all-cause and CV mortality. The distributions of FGF23 and CACS were markedly skewed. Prior to the Cox proportional hazards analyses, FGF23 was transformed to Log FGF23 and CACS was transformed to Log (CACS + 1), because some of the study participants had a CACS of 0.

Results {#Sec4}
=======

The MHD patients' primary diseases were as follows: diabetic nephropathy (*n* = 142, 40.2%), chronic glomerulonephritis (*n* = 121, 34.3%), nephrosclerosis (*n* = 43, 12.2%), polycystic kidney disease (*n* = 11, 3.1%), other diseases (*n* = 13, 3.7%), and unknown conditions (*n* = 23, 6.5%). The baseline characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. Among all patients (*n* = 353), the median (IQR) age was 68 (60--78) years and 66.6% were male. The median (IQR) dialysis vintage was 75 (32--151) months. The median (IQR) Mg level was 2.4 (2.2--2.7) mg/dl; four (1.1%) patients had Mg \< 1.7 mg/dl, 179 (50.7%) patients had Mg values in the normal range for the general population (1.7--2.4 mg/dl), and 170 (48.2%) patients had Mg \> 2.4 mg/dl. The same Mg values were observed in many patients in this study, and the groups were not correctly divided into quartiles; notably, the four groups according to Mg differed considerably in the numbers of patients. Mg levels were \< 2.2 mg/dl, 2.2--2.4 mg/dl, 2.5--2.7 mg/dl, and \> 2.7 mg/dl in group (G)1 (*n* = 86), G2 (*n* = 97), G3 (*n* = 99), and G4 (*n* = 71), respectively. Our study showed that age, dialysis vintage, average ultrafiltration, frequency of warfarin use, serum potassium, hsCRP, phosphate, uric acid, albumin, and FGF23 levels were significantly different among the four groups (*P* \< 0.05). There were also significant differences in nPNA \[0.80 (0.60--0.92), 0.89 (0.78--1.04), 0.94 (0.83--1.05), and 0.97 (0.85--1.11) g/kg/day, *P* \< 0.0001\], GNRI \[89 (80--94), 92 (86--97), 94 (91--98), and 95 (89--98), *P* \< 0.0001\], Kt/Vurea \[1.30 (1.12--1.46), 1.40 (1.25--1.56), 1.41 (1.30--1.62), and 1.42 (1.26--1.57)/session, *P* = 0.0003\], and diastolic blood pressure \[77 ± 15, 79 ± 14, 82 ± 13, and 83 ± 14 mmHg, *P* = 0.0003\] in G1, G2, G3 and G4 (data not shown). No significant differences were detected among the four groups in the frequency of male gender, frequency of diabetes mellitus, frequency of urine volume ≥ 100 ml/day, CACS, or iPTH values. Furthermore, no significant differences were detected in albumin-adjusted serum calcium \[9.4 (8.9--10.0), 9.3 (8.9--9.8), 9.5 (9.0--10.0), and 9.4 (9.1--10.1) mg/dl, *P* = 0.5318\] and systolic blood pressure \[147 ± 25, 146 ± 23, 150 ± 20, and 154 ± 22 mmHg, *P* = 0.2221\] in G1, G2, G3 and G4 (data not shown).

Table 1Baseline characteristics of maintenance hemodialysis patients (*n* = 353), stratified by the serum magnesium valueCharacteristicsAllGroup 1Group 2Group 3Group 4*P*(Mg \< 2.2 mg/dl)(Mg 2.2--2.4 mg/dl)(Mg 2.5--2.7 mg/dl)(Mg \> 2.7 mg/dl)*n* = 353*n* = 86*n* = 97*n* = 99*n* = 71Serum magnesium (mg/dl)2.4 (2.2--2.7)2.0 (1.9--2.1)2.3 (2.2--2.4)2.6 (2.5--2.7)2.9 (2.8--3.1)\< 0.0001Age (years)68 (60--78)73 (64--80)71 (62--79)66 (59--73)63 (55--73)\< 0.0001Gender (male), *n* (%)235/353 (66.6)62/86 (72.1)62/97 (63.9)66/99 (66.7)45/71 (63.4)0.6126Dialysis vintage (months)75 (32--151)55 (23--105)60 (28--126)85 (46--175)93 (48--183)0.0044Diabetes mellitus, *n* (%)142/353 (40.2)41/86 (47.7)37/97 (38.1)36/99 (36.7)28/71 (39.4)0.4454Urine volume ≥ 100 ml/day, *n* (%)87/353 (24.6)20/86 (23.2)31/97 (32.0)21/99 (21.2)15/71 (21.1)0.2631Average ultrafiltration (ml/kg/h)11.2 ± 3.110.4 ± 3.511.0 ± 2.811.7 ± 2.611.8 ± 3.50.0122CACS1181 (278--3190)1550 (318--3715)1145 (254--2872)1030 (247--2520)1057 (257--2357)0.5483Warfarin use, *n* (%)39/353 (11.0)15/86 (17.4)4/97 (4.1)15/99 (15.1)5/71 (7.0)0.0109Serum potassium (mEq/l)4.7 ± 0.84.3 ± 0.84.6 ± 0.75.0 ± 0.75.0 ± 0.8\< 0.0001Serum hsCRP (mg/dl)0.12 (0.04--0.43)0.26 (0.06--0.80)0.12 (0.03--1.49)0.12 (0.03--0.35)0.07 (0.03--0.19)\< 0.0008Serum phosphate (mg/dl)5.1 (4.1--6.0)4.2 (3.2--5.4)5.2 (4.2--6.1)5.3 (4.7--6.3)5.1 (4.4--6.1)\< 0.0001Serum uric acid (mg/dl)7.3 ± 1.46.6 ± 1.47.4 ± 1.47.4 ± 1.17.6 ± 1.5\< 0.0001Serum intact parathyroid hormone (pg/ml)109 (51--208)107 (49--183)110 (57--210)128 (60--241)97 (38--183)0.1247Serum albumin (g/dl)3.6 (3.3--3.8)3.3 (2.9--3.6)3.6 (3.3--3.8)3.6 (3.4--3.8)3.7 (3.5--3.9)\< 0.0001FGF23 (pg/ml)3165 (590--11075)784 (247--5510)3210 (769--11650)4470 (1305--13425)4680 (1150--11500)\< 0.0001Mg, serum magnesium; Diabetes mellitus, presence of diabetes mellitus; Average ultrafiltration (ml/kg/h), average ultrafiltration/body weight before treatment in the first hemodialysis session of the week in September 2014 (ml/kg/h); CACS, coronary artery calcium score; Warfarin use, current use of warfarin; hsCRP, high-sensitivity C-reactive protein; FGF23, intact fibroblast growth factor 23

Ninety-one patients died during the 3-year observation period, and the 3-year cumulative survival rate in all subjects was 73.3%. CV disease (51.6%, 47/91) was the primary cause of death, followed by infection (30.8%, 28/91), malignancy (3.3%, 3/91), other causes (11.0%, 10/91), and unknown conditions (3.3%, 3/91). Kaplan--Meier plots showed that 3-year overall survival for all-cause mortality was 59.0% in patients with Mg value below the median value (\< 2.4 mg/dl, *n* = 136) and 82.3% in patients with Mg value above the median value (≥ 2.4 mg/dl, *n* = 217). The HR (95% CI) for 3-year all-cause death in patients with Mg \< 2.4 mg/dl was 2.79 (1.84--4.27), *P* \< 0.0001 (Fig. [1](#Fig1){ref-type="fig"}a). However, 3-year cumulative survival for all-cause mortality in patients with Mg \< 2.4 mg/dl did not differ significantly from that of patients with Mg ≥ 2.4 mg/dl in all subgroups that were analyzed, including those with serum albumin of quartile (Q)1 \[3.0 (2.7--3.2) g/dl, *n* = 88\], serum albumin of Q2 \[3.5 (3.4--3.5) g/dl, *n* = 88\], serum albumin of Q3 \[3.7 (3.6--3.7) g/dl, *n* = 88\], and serum albumin of Q4 \[3.9 (3.8--3.9) g/dl, *n* = 89\] (Fig. [1](#Fig1){ref-type="fig"}b--e).

Fig. 1Kaplan--Meier overall 3-year survival for all-cause death (**a**) and 3-year survival for all-cause death in subgroups according to serum albumin quartiles (**b**--**e**). Overall survival was worse in patients with Mg values below the median value (\< 2.4 mg/dl, *n* = 136) than in patients with Mg values above the median value (≥ 2.4 mg/dl, *n* = 217). The hazard ratio for death (95% confidence interval) was 2.79 (1.84--4.27), *P* \< 0.0001 (**a**). However, the significant difference was lost in subgroup analyses according to serum albumin quartiles. Mg, serum magnesium; No., numbers; CI, confidence interval

Kaplan--Meier plots also showed significantly worse overall 3-year survival for CV mortality in patients with Mg \< 2.4 mg/dl (*n* = 136), compared with that in patients with Mg ≥ 2.4 mg/dl (*n* = 217); the HR (95% CI) for 3-year CV death in patients with Mg \< 2.4 mg/dl was 3.73 (2.07--6.98), *P* \< 0.0001(Fig. [2](#Fig2){ref-type="fig"}a). However, 3-year cumulative survival for CV mortality in patients with Mg \< 2.4 mg/dl did not differ significantly from that of patients with Mg ≥ 2.4 mg/dl in all subgroups that were analyzed, including those with serum albumin of Q1, Q2, Q3, and Q4 (Fig. [2](#Fig2){ref-type="fig"}b--e).

Fig. 2Kaplan--Meier overall 3-year survival for cardiovascular (CV) mortality (**a**) and 3-year survival for CV mortality in subgroups according to serum albumin quartiles (**b**--**e**). Overall survival for CV death was worse in patients with Mg values below the median value (\< 2.4 mg/dl, *n* = 136) than in patients with Mg values greater than the median value (≥ 2.4 mg/dl, *n* = 217). The hazard ratio (95% confidence interval) for CV death was 3.73 (2.07--6.98), *P* \< 0.0001 (**a**). However, the significant difference for CV mortality was lost in subgroup analyses when serum albumin quartiles were incorporated (**b**--**e**). Mg, serum magnesium; No., numbers; CI, confidence interval

The predictors of 3-year all-cause mortality in MHD patients by Cox proportional hazard analyses are shown in Table [2](#Tab2){ref-type="table"}. They included the age, dialysis vintage, average ultrafiltration, Log (CACS + 1), warfarin use, serum potassium, hsCRP, phosphate, uric acid, iPTH, Mg \< 2.4 mg/dl, serum albumin, gender (male), presence of diabetes mellitus, urine volume ≥ 100 ml/day, and Log FGF23 at baseline. In the univariate analyses, all variables except gender (male), presence of diabetes mellitus, urine volume ≥ 100 ml/day, and Log FGF23 were significantly associated with 3-year all-cause mortality (*P* \< 0.05). In multivariate analyses, Mg \< 2.4 mg/dl was a significant all-cause mortality risk factor independent of age, dialysis vintage, average ultrafiltration, Log (CACS + 1), warfarin use, serum potassium, hsCRP, phosphate, uric acid, and iPTH in model 1 \[HR (95% CI) 2.82 (1.31--6.29), *P* = 0.0078\]. However, the statistical significance of Mg \< 2.4 mg/dl was lost in model 2, which included the same variables as model 1 plus serum albumin.

Table 2Predictors of 3-year all-cause mortality in maintenance hemodialysis patients, according to Cox proportional hazard analyses (*n* = 353)Independent variableUnivariate analysesMultivariate analysesModel 1Model 2HR95% CI*P*HR95% CI*P*HR95% CI*P*Age (years)1.081.06--1.11\< 0.00011.071.03--1.120.00021.061.01--1.100.0088Dialysis vintage (months)1.000.99--1.00\< 0.00911.000.99--1.000.50281.000.99--1.000.8750Average ultrafiltration (ml/kg/h)0.930.86--0.990.02950.990.87--1.130.87000.980.87--1.120.8109Log (CACS + 1)2.071.24--3.840.00361.741.01--3.260.04721.991.03--3.840.0246Warfarin use2.511.47--4.080.00123.881.75--8.170.00134.522.03--9.540.0004Serum potassium (mEq/l)0.600.45--0.790.00021.280.70--2.310.41721.530.81--2.870.1878Serum hsCRP (mg/dl)1.571.39--1.77\< 0.00011.200.88--1.570.22571.120.84--1.490.4623Serum phosphate (mg/dl)0.730.63--0.84\< 0.00011.070.78--1.460.67951.170.86--1.600.3191Serum uric acid (mg/dl)0.630.53--0.75\< 0.00010.790.55--1.100.16580.870.62--1.220.4152Intact parathyroid hormone (pg/ml)1.000.99--1.000.03570.990.99--1.000.96941.000.99--1.000.8527Serum Mg \< 2.4 mg/dl2.791.84--4.27\< 0.00012.821.31--6.290.00782.170.96--5.020.0633Serum albumin (g/dl)0.130.10--0.19\< 0.00010.210.09--0.490.0007Gender (male)0.870.57--1.350.5262Diabetes mellitus1.390.92--2.090.1205Urine volume ≥ 100 ml/day0.670.39--1.100.1136Log FGF23 (pg/ml)1.000.99--1.000.1086Model 1 included age, dialysis vintage, average ultrafiltration, Log (CACS + 1), warfarin use, serum potassium, hsCRP, phosphate, uric acid, intact parathyroid hormone, and serum Mg \< 2.4 mg/dl, which exhibited significance in the univariate analyses; serum albumin was excluded. Model 2 included the same variables as model 1 plus serum albuminMg, magnesium; Diabetes mellitus, presence of diabetes mellitus; Average ultrafiltration (ml/kg/h), average ultrafiltration/body weight before treatment in the first hemodialysis session of the week in September 2014 (ml/kg/h); CACS, coronary artery calcium score; Warfarin use, current use of warfarin; hsCRP, high-sensitivity C-reactive protein; FGF23, intact fibroblast growth factor 23; HR, hazard ratio; CI, confidence interval

The predictors of 3-year CV mortality identified in MHD patients by Cox proportional hazard analyses are shown in Table [3](#Tab3){ref-type="table"}. The same independent variables in Table [2](#Tab2){ref-type="table"} were included in the univariate Cox models. In the univariate analyses, the age, dialysis vintage, Log (CACS + 1), warfarin use, serum hsCRP, uric acid, Mg \< 2.4 mg/dl, and serum albumin were found to be significantly associated with 3-year CV mortality (*P* \< 0.05). However, other variables, including the gender (male), presence of diabetes mellitus, urine volume ≥ 100 ml/day, average ultrafiltration, serum potassium, phosphate, iPTH, and Log FGF23, were not. Multivariate analyses showed that Mg \< 2.4 mg/dl was significantly associated with 3-year CV mortality, independent of age, dialysis vintage, Log (CACS + 1), warfarin use, serum hsCRP, and uric acid in model 1 \[HR (95% CI): 4.47 (1.45--16.76), *P* = 0.0086\]. However, the statistical significance of Mg \< 2.4 mg/dl was lost in model 2, which included the same variables as model 1 plus serum albumin.

Table 3Predictors of 3-year cardiovascular mortality in maintenance hemodialysis patients, according to Cox proportional hazard analyses (*n* = 353)Independent variableUnivariate analysesMultivariate analysesModel 1Model 2HR95% CI*P*HR95% CI*P*HR95% CI*P*Age (years)1.081.05--1.11\< 0.00011.091.03--1.180.00581.081.01--1.170.0251Dialysis vintage (months)1.000.99--1.000.00911.001.00--1.010.54291.000.99--1.010.8450Log (CACS + 1)2.941.21--9.210.01262.461.03--7.270.04162.791.06--9.060.0372Warfarin use2.931.42--5.580.00496.211.95--19.130.00297.272.22--23.040.0017Serum hsCRP (mg/dl)1.571.29--1.84\< 0.00011.060.65--1.500.79241.030.58--1.400.8834Serum uric acid (mg/dl)0.690.54--0.870.00121.180.81--1.730.39791.500.99--2.330.0568Serum Mg \< 2.4 mg/dl3.732.07--6.98\< 0.00014.471.45--16.760.00862.560.72--10.360.1485Serum albumin (g/dl)0.150.09--0.24\< 0.00010.150.04--0.570.0062Gender (male)0.830.46--1.540.5424Diabetes mellitus1.470.83--2.620.1859Urine volume ≥ 100 ml/day0.870.48--1.680.6725Average ultrafiltration (ml/kg/h)0.940.85--1.030.1947Serum potassium (mEq/l)0.690.47--1.010.0565Serum phosphate (mg/dL)0.930.76--1.140.4977Intact parathyroid hormone (pg/ml)1.000.99--1.000.5725Log FGF23 (pg/ml)1.000.99--1.000.3003Model 1 included age, dialysis vintage, Log (CACS + 1), warfarin use, serum hsCRP, uric acid, and serum Mg \< 2.4 mg/dl, which exhibited significance in the univariate analyses; serum albumin was excluded. Model 2 included the same variables as model 1 plus serum albuminMg, magnesium; Diabetes mellitus, presence of diabetes mellitus; Average ultrafiltration (ml/kg/h), average ultrafiltration/body weight before treatment in the first hemodialysis session of the week in September 2014 (ml/kg/h); CACS, coronary artery calcium score; Warfarin use, current use of warfarin; hsCRP, high-sensitivity C-reactive protein; FGF23, intact fibroblast growth factor 23; HR, hazard ratio; CI, confidence interval

Discussion {#Sec5}
==========

The estimation of total body magnesium stores based on serum levels can be problematic as this fraction is not necessarily readily exchangeable with other body compartments. However, the most common method of clinical assessment of magnesium balance remains the total Mg \[[@CR4]\]. Recently, there has been an increasing number of clinical reports regarding the associations between Mg levels and mortality and CV mortality in HD patients. Most studies found that lower Mg levels were associated with increased all-cause and CV mortality \[[@CR9], [@CR13]--[@CR15]\]. However, Ishimura et al. reported that all-cause and non-CV mortality (but not CV mortality) were associated with lower Mg levels \[[@CR16]\]. Our study showed worse 3-year cumulative overall survival for all-cause and CV death in patients with hypomagnesemia (Mg \< 2.4 mg/dl); however, the significance was lost when serum albumin quartile was incorporated in the models. Cox proportional hazard analyses in our study showed that Mg \< 2.4 mg/dl was a significant 3-year all-cause mortality risk factor, independent of age, dialysis vintage, average ultrafiltration, Log (CACS + 1), warfarin use, serum potassium, hsCRP, phosphate, uric acid, and iPTH. Furthermore, Mg \< 2.4 mg/dl was a significant predictor of 3-year CV death, independent of age, dialysis vintage, Log (CACS + 1), warfarin use, serum hsCRP, and uric acid. However, upon inclusion of serum albumin in the models, the all-cause and CV mortality risk prediction of hypomagnesemia was lost. This indicates that hypomagnesemia alone was not an independent predictor of all-cause and CV mortality, but was associated with malnutrition. The median (IQR) age was 68 (60--78) years and the 3-year cumulative survival rate was 73.3% in our subjects; these were consistent with the 3-year cumulative survival rate (72.9%) in Japanese MHD patients for a similar median age \[[@CR17]\]. This seems relevant for generalization of the results, at least in Japanese patients.

A cohort study of 142,555 Japanese HD patients by Sakaguchi et al. \[[@CR8]\] and a study of 206 HD patients by Matias et al. \[[@CR13]\] revealed that hypomagnesemia is a significant mortality risk factor, independent of malnutrition; this is inconsistent with our results. Notably, all three of those studies were prospective observational studies; the observational period was 1--2 years in those studies and 3 years in our study. It has been reported that MHD patients tend to exhibit higher Mg levels than healthy controls \[[@CR4], [@CR18]\]. The frequency of hypermagnesemia (\> 2.4 mg/dl) in our study was 170/353 (48.2%), which is lower than the frequencies reported by Sakaguchi et al. \[87,993/142,555 (61.7%)\] \[[@CR8]\] or Matias et al. \[197/206 (95.5%)\] \[[@CR13]\]. The different results in these studies may be explained by changes in magnesium balance in the analyzed patients, perhaps due to low food intake, processed foods with a low magnesium content in patients, and low dialysate magnesium concentration (1 mEq/l) in Japan, compared with the dialysate used by Matias et al. (2.0 mEq/l). There is a possibility that the lower frequency of hypermagnesemia in our study may mask some positive effect of Mg in our cohort. Sakaguchi et al. detected a J-shaped relationship between Mg levels and mortality, in which Mg levels of \< 2.7 mg/dl and ≥ 3.1 mg/dl were associated with increased risks of all-cause mortality \[[@CR8]\]. Optimal Mg concentration in HD patients may be above the reference range for the general population. We agree with the suggestion by Sakaguchi et al. that it is important to determine both the lower and upper limits of the target range of Mg in HD patients \[[@CR8]\], because hypermagnesemia has been linked to osteomalacia; moreover, activation of the calcium-sensing receptor results in lower PTH levels \[[@CR3], [@CR19]\]. Further studies are needed to determine optimal Mg levels and dialysate magnesium concentrations for HD patients.

It has been reported that lower Mg levels are associated with reduced serum phosphorus, calcium, and albumin levels; thus, they might be indicative of malnutrition \[[@CR9], [@CR16], [@CR20]\]. It has also been reported that lower Mg levels are linked with poorer nutritional status and increased inflammation \[[@CR21]\]. A large study found that hypomagnesemia (\< 1.9 mg/dl) conferred an increased risk of mortality solely in the presence of low-serum albumin levels (\< 35 g/l) \[[@CR22]\]. In our study, MHD patients with Mg \< 2.4 mg/dl had worse nutritional status, which comprised lower values of serum albumin, nPNA, GNRI, phosphate, and uric acid, compared with patients with Mg ≥ 2.4 mg/dl. Taken together with the results of the previous reports \[[@CR9], [@CR16], [@CR20]--[@CR22]\], our findings indicate that nutritional factors greatly influence hypomagnesemia, and that such factors might partly contribute to the poor outcomes described by Courivaud et al. \[[@CR11]\]. Thus, hypomagnesemia appears to be correlated with mortality; whether Mg plays a causal role in this relationship remains unclear \[[@CR4], [@CR11]\].

The presence of diabetes mellitus, FGF23 levels, and existing residual renal function were not significant predictors for 3-year all-cause and CV mortality in MHD patients in our study. We cannot completely exclude relevant bias in the analyses, but we have contemplated our results as below. The reported 5-year cumulative survival rates of HD patients with and without diabetes were 47% versus 31%, while corresponding 10-year cumulative survival rates were 22% versus 31% \[*P* = 0.03\]; the paths of the two groups were divergent at 5 years, suggesting that patients with diabetes may experience early mortality \[[@CR23]\]. Early mortality in diabetic HD patients may be partly explained by the lack of an association between the presence of diabetes mellitus and mortality in our study, because our subjects were not incident HD patients and the median (IQR) dialysis vintage was 75 (32--151) months. The association of serum FGF23 levels and mortality in HD patients has been frequently described \[[@CR24], [@CR25]\]; however, no association was reported by Olauson et al. \[[@CR26]\], which is consistent with our results. Discrepancies between these studies might be partly explained by the contributions of previous CV diseases, residual renal function levels, variations in the prevalence of diabetes \[[@CR27]\], and racial differences. Urine volume ≥ 100 ml/day was used as a surrogate marker for residual renal function in this study, as in previous reports \[[@CR28], [@CR29]\]. An association between residual renal function (urine volume ≥ 100 ml/day) and mortality in MHD patients was not observed in our study, in contrast to previous reports \[[@CR28], [@CR29]\]; this may be related to the lower frequency of patients with residual renal function in our study \[87/353 (24.6%) patients\].

Our data did not show a significant difference of CACS between patients with Mg \< 2.4 mg/dl and patients with Mg ≥ 2.4 mg/dl, in contrast to previous experimental studies \[[@CR5]--[@CR7]\]. However, we suspect that the lack of a cross-sectional association does not exclude a potential impact of persistently low Mg levels on CACS progression.

This study has several limitations. First, the study was a single analysis of laboratory values only at baseline. Therefore, there was no time-averaged analysis of laboratory data, and the influence of a single serum sample of magnesium, FGF23, or potassium value on 3-year all-cause and CV mortality might exhibit wide variation. Second, because the subjects were all Japanese MHD patients, the results might not be applicable to other populations. Third, the sample size and number of deaths were relatively small; therefore, the Cox regression analyses were restricted to a limited number of potential confounders. Fourth, there was no information regarding oral magnesium intake among these patients.

In conclusion, MHD patients with hypomagnesemia showed significantly worse 3-year cumulative survival for all-cause and CV death. Importantly, hypomagnesemia was not an independent risk factor for all-cause and CV mortality, but was associated with malnutrition in MHD patients.
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